The University of Southampton
University of Southampton Institutional Repository

Osteoporosis and CKD-metabolic bone disease under the same umbrella: insights from a joint scientific symposium

Osteoporosis and CKD-metabolic bone disease under the same umbrella: insights from a joint scientific symposium
Osteoporosis and CKD-metabolic bone disease under the same umbrella: insights from a joint scientific symposium

Osteoporosis and chronic kidney disease (CKD)-metabolic bone disease (MBD) (CKD-MBD) are increasingly recognized as overlapping conditions, particularly in the aging population. Declining renal function and skeletal fragility often coexist, because CKD-MBD may develop in a skeleton already compromised by preexisting osteoporosis. Adynamic bone, often resulting from excessive suppression of parathyroid hormone (PTH) and now a common form of renal osteodystrophy (ROD), may histologically resemble low-turnover osteoporosis; distinguishing between the 2 under light microscopy remains difficult, and reliable differentiation often depends on clinical context. Nevertheless, nephrologists and nonnephrologist bone specialists frequently work in parallel rather than in collaboration.This separation has contributed to persistent diagnostic gaps and fragmented management, especially in patients with advanced CKD. Advances in imaging, biochemical markers, and bone histomorphometry have improved insight into disease mechanisms; however, limitations in current diagnostic approaches remain. Osteoporosis therapies are frequently underused in CKD, despite growing evidence supporting efficacy and safety across a broader range of kidney function than previously assumed. Despite efforts to refine the definition of osteoporosis beyond bone mineral density (BMD) alone, clinical misclassification continues.Beyond skeletal health, vascular calcification (VC)-driven by disordered calcium-phosphate homeostasis-remains insufficiently prioritized in clinical decision-making, despite its strong association with cardiovascular morbidity and mortality in CKD. Emerging concepts, such as intermittent PTH administration, an established treatment in osteoporosis, illustrate the potential for interventions that may restore mineral balance and improve skeletal integrity in selected CKD populations. Whether such strategies can also favorably influence cardiovascular risk remains uncertain and warrant investigation. This integrated framework may improve interdisciplinary care.

CKD-MBD, osteoporosis, renal osteodystrophy, vascular calcification
2468-0249
Dempster, David W.
060fe34f-77f9-4a60-a83c-05ff78638116
Evenepoel, Pieter
20c46a65-fce6-444f-aa2d-c30120ed5e1d
Nickolas, Thomas L.
928065d5-47bb-4cf7-8084-8d33fccde988
Massy, Ziad A.
66f49e03-d6da-4451-bfe1-734f3e68a86a
Mazzaferro, Sandro
c6584be6-6836-443f-adc2-bbbc97655f7b
Harvey, Nicholas C.
ce487fb4-d360-4aac-9d17-9466d6cba145
Miller, Paul D.
d08ce2e7-dc60-4511-b065-70da5b36158c
Pazianas, Michael
dcba1270-21c4-4b16-b0ca-4ec9ad12eecc
Dempster, David W.
060fe34f-77f9-4a60-a83c-05ff78638116
Evenepoel, Pieter
20c46a65-fce6-444f-aa2d-c30120ed5e1d
Nickolas, Thomas L.
928065d5-47bb-4cf7-8084-8d33fccde988
Massy, Ziad A.
66f49e03-d6da-4451-bfe1-734f3e68a86a
Mazzaferro, Sandro
c6584be6-6836-443f-adc2-bbbc97655f7b
Harvey, Nicholas C.
ce487fb4-d360-4aac-9d17-9466d6cba145
Miller, Paul D.
d08ce2e7-dc60-4511-b065-70da5b36158c
Pazianas, Michael
dcba1270-21c4-4b16-b0ca-4ec9ad12eecc

Dempster, David W., Evenepoel, Pieter, Nickolas, Thomas L., Massy, Ziad A., Mazzaferro, Sandro, Harvey, Nicholas C., Miller, Paul D. and Pazianas, Michael (2026) Osteoporosis and CKD-metabolic bone disease under the same umbrella: insights from a joint scientific symposium. Kidney International Reports, 11 (5), [106362]. (doi:10.1016/j.ekir.2026.106362).

Record type: Article

Abstract

Osteoporosis and chronic kidney disease (CKD)-metabolic bone disease (MBD) (CKD-MBD) are increasingly recognized as overlapping conditions, particularly in the aging population. Declining renal function and skeletal fragility often coexist, because CKD-MBD may develop in a skeleton already compromised by preexisting osteoporosis. Adynamic bone, often resulting from excessive suppression of parathyroid hormone (PTH) and now a common form of renal osteodystrophy (ROD), may histologically resemble low-turnover osteoporosis; distinguishing between the 2 under light microscopy remains difficult, and reliable differentiation often depends on clinical context. Nevertheless, nephrologists and nonnephrologist bone specialists frequently work in parallel rather than in collaboration.This separation has contributed to persistent diagnostic gaps and fragmented management, especially in patients with advanced CKD. Advances in imaging, biochemical markers, and bone histomorphometry have improved insight into disease mechanisms; however, limitations in current diagnostic approaches remain. Osteoporosis therapies are frequently underused in CKD, despite growing evidence supporting efficacy and safety across a broader range of kidney function than previously assumed. Despite efforts to refine the definition of osteoporosis beyond bone mineral density (BMD) alone, clinical misclassification continues.Beyond skeletal health, vascular calcification (VC)-driven by disordered calcium-phosphate homeostasis-remains insufficiently prioritized in clinical decision-making, despite its strong association with cardiovascular morbidity and mortality in CKD. Emerging concepts, such as intermittent PTH administration, an established treatment in osteoporosis, illustrate the potential for interventions that may restore mineral balance and improve skeletal integrity in selected CKD populations. Whether such strategies can also favorably influence cardiovascular risk remains uncertain and warrant investigation. This integrated framework may improve interdisciplinary care.

Text
main (4) - Version of Record
Available under License Creative Commons Attribution.
Download (1MB)

More information

Accepted/In Press date: 9 February 2026
e-pub ahead of print date: 17 February 2026
Published date: 10 March 2026
Keywords: CKD-MBD, osteoporosis, renal osteodystrophy, vascular calcification

Identifiers

Local EPrints ID: 511269
URI: http://eprints.soton.ac.uk/id/eprint/511269
ISSN: 2468-0249
PURE UUID: 0a10a1f0-b540-4aa0-9a41-4ddf46a86881
ORCID for Nicholas C. Harvey: ORCID iD orcid.org/0000-0002-8194-2512

Catalogue record

Date deposited: 11 May 2026 16:40
Last modified: 12 May 2026 01:41

Export record

Altmetrics

Contributors

Author: David W. Dempster
Author: Pieter Evenepoel
Author: Thomas L. Nickolas
Author: Ziad A. Massy
Author: Sandro Mazzaferro
Author: Paul D. Miller
Author: Michael Pazianas

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×